Dipeptidyl peptidase-4 inhibitors and the incidence of inflammatory bowel disease among patients with type 2 diabetes.

Dipeptidyl peptidase-4 inhibitors and the incidence of inflammatory bowel disease among patients with type 2 diabetes.

Abrahami D, Douros A, Yin H, Renoux C, Yu OHY, Bitton A, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the incidence of inflammatory bowel disease among patients with type 2 diabetes. BMJ 2018 Mar; 21;360:k872.

View All Publications